Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.37 |
| ▸ | ITGAL | P20701 | 4/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021007 | 0.95 | MEN1 (0.43) | MEN1ALDH1A1KMT2APLATSPHK2 | |
| SCHEMBL15020808 | 0.91 | ALDH1A1 (0.44) | MEN1ALDH1A1KMT2APLATSPHK2 | |
| SCHEMBL15020591 | 0.91 | MEN1 (0.46) | MEN1ALDH1A1KMT2APLATSPHK2 | |
| SCHEMBL15021376 | 0.91 | KMT2A (0.45) | MEN1ALDH1A1KMT2APLATSPHK2 | |
| SCHEMBL256817 | 0.91 | KMT2A (0.45) | MEN1ALDH1A1KMT2APLATSPHK2 | |
| SCHEMBL15042205 | 0.90 | MEN1 (0.46) | MEN1ALDH1A1KMT2APLATSPHK2 | |
| SCHEMBL15020701 | 0.89 | KMT2A (0.44) | MEN1ALDH1A1KMT2APLATSPHK2 | |
| SCHEMBL15020530 | 0.88 | MEN1 (0.43) | MEN1ALDH1A1KMT2APLATSPHK2 | |
| SCHEMBL15020705 | 0.88 | MAPT (0.45) | ALDH1A1CDK1ITGB2ICAM1ITGAL | |
| SCHEMBL257291 | 0.88 | MAPT (0.47) | MEN1ALDH1A1KMT2APLATSPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | claimed |
| EP-2617723-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | Amorepacific Corporation (KR) | 2013-07-24 | — | — | EP | claimed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | claimed |
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | disclosed |
| EP-2617723-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | Amorepacific Corporation (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | CNR1, CNR2, GPR18 | MEN1 3752/4885ALDH1A1 2139/4885KMT2A 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.